A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
The study will last about 220 weeks and may include up to 23 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
- Participants must have completed the last visit of an eligible study period of originating study
- Participants must be willing to follow the birth control measures during and after study treatment if woman of childbearing potential
- Participants must not have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, liver, kidney, gastrointestinal, endocrine, blood, or neurologic disease or abnormal lab results, that the study investigator thinks makes it unsafe or inappropriate for the participant to participate in this study
- Participants must not have stopped taking mirikizumab during a previous study if the study investigator does not think the participant should resume taking mirikizumab